Search Results for :


Two New Studies at the 2018 AAD Annual Meeting Highlight the Clinical Impact and Utilization of the DecisionDx-Melanoma Test for Cutaneous Melanoma

San Diego, CA – February 16, 2018 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the presentation of two studies highlighting the clinical use of the DecisionDx®-Melanoma gene expression profile test, which uses tumor biology to provide an individual risk of recurrence in cutaneous melanoma patients. The … Read More


DecisionDx-Melanoma Test for Cutaneous Melanoma Validated in Two Prospective Multicenter Study Cohorts to Provide Guidance for Sentinel Lymph Node Biopsy Recommendations

San Diego, CA – February 16, 2018 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the presentation of a study highlighting research on a new clinical use for the DecisionDx®-Melanoma gene expression profile test to guide sentinel lymph node biopsy (SLNB) recommendations. The study titled, “A Prospective … Read More


Castle Biosciences Launches Next-Generation Sequencing Panel DecisionDx-UMSeq for Uveal Melanoma

Friendswood, TX – January 8, 2018 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-UMSeq panel that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to uveal melanoma (UM). The new test will complement Castle Biosciences’ standard-of-care DecisionDx®-UM gene expression … Read More


Frank Stokes

Frank Stokes has more than 20 years of experience in finance, including extensive experience leading capital formation for high-growth healthcare and life science companies.  Most recently he was CFO of Hammock Pharmaceuticals where he assisted in the initial capitalization of the company as well as the acquisition of Hammock’s foundational drug delivery technology.  Previously Frank … Read More


Castle Biosciences Announces the Appointment of Frank Stokes as Chief Financial Officer

Friendswood, TX – December 7, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the appointment of Frank Stokes as Chief Financial Officer (CFO). Mr. Stokes has extensive experience leading capital formation for high-growth companies, most recently as CFO of Hammock Pharmaceuticals and previously as a Senior … Read More


Castle Biosciences to Present at the Piper Jaffray 29th Annual Healthcare Conference

Friendswood, TX – November 20, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO will be presenting at the Piper Jaffray 29th Annual Healthcare Conference on Tuesday, November 28th, 2017 at 8:10 a.m. ET in New York City.
About Castle Biosciences
Read More


Watch the Replay of Federico Monzon, MD’s Presentation Webcast at the Cancer Research & Oncology Live Virtual Event

Catch the on-demand replay of “Personalizing Melanoma Management with Molecular Diagnostics” presented by Castle Biosciences’ Federico Monzon, MD. The presentation provides an overview of the use of molecular diagnostics in melanoma, from screening to monitoring therapy, and was part of a virtual event that focused on advancements in prevention, diagnosis and … Read More